Rifaximin, a non-systemic antibiotic, is the standard of care for addressing SIBO [1]. However, it doesn’t work in over 50% of the patients [2]. The fortunate ones get their symptoms reduced but are rarely cured [3]. Further, 64% of the patients who benefit from Rifaximin relapse within a few months [4]. Clearly, a better solution for SIBO is required.
Prior to any serious discussion of potential therapeutic solutions, it is necessary to characterize the small intestinal microbiome and the pathogens behind SIBO. There are relatively few studies that have investigated this because of the technical challenges involved in the intrusive process of extracting duodenal or jejunal aspirate samples. We will highlight the noteworthy ones.
Read more 
Pathogens Behind SIBO And Limitations of Rifaximin
/in Antimicrobials, SIBO/by Sumit KhetarpalRifaximin, a non-systemic antibiotic, is the standard of care for addressing SIBO [1]. However, it doesn’t work in over 50% of the patients [2]. The fortunate ones get their symptoms reduced but are rarely cured [3]. Further, 64% of the patients who benefit from Rifaximin relapse within a few months [4]. Clearly, a better solution for SIBO is required.
Prior to any serious discussion of potential therapeutic solutions, it is necessary to characterize the small intestinal microbiome and the pathogens behind SIBO. There are relatively few studies that have investigated this because of the technical challenges involved in the intrusive process of extracting duodenal or jejunal aspirate samples. We will highlight the noteworthy ones.
Read morePrincipal Scientist – Strain Engineering
/in Jobs/by Sumit KhetarpalAn estimated 700 million patients worldwide suffer from IBS. At Gutbiotics, our mission is to end IBS. We are developing genetically engineered bacteria that release antimicrobial peptides in the intestines and eliminate the IBS causing pathogens. In addition, the genetically engineered bacteria promote a healthy intestinal environment due to their probiotic nature.
We are seeking a Principal Scientist to drive our genetically engineered biotherapeutic development. We are not looking for an expert who has been there and done that, but someone with a learner mindset who is excited about our mission, and willing to pick up the necessary skills. You will get to work with an accomplished team that has developed a comprehensive patent portfolio around intestinal health and grow from their mentorship.
Read moreA Tale Of Ineffective Antibiotics – Meet A SIBO Warrior Abigail Dancause
/in Meet The Warriors/by Sumit KhetarpalWe sat down with Abigail Dancause – a competent healthcare professional who has been battling SIBO for the last seven years. Here are some of the things that jumped out:
Listen to the entire discussion below
The Future of Anti-Microbials For SIBO – A Discussion With Dr. Bryan Davies
/in Antimicrobials/by Sumit KhetarpalDr. Bryan Davies is one of the leading researchers in the field of antimicrobial discovery and development. We had an insightful discussion with him on the future of anti-microbials for SIBO. Here are the highlights:
A Better Antibiotic For Small Intestinal Bacterial Overgrowth | Target Product Profile
/in Antimicrobials/by Sumit KhetarpalAn estimated 700 million people are adversely affected by irritable bowel syndrome (IBS), that is one out of every ten people in the world. While IBS is not a life-threatening disease, it has a significant impact on quality of life. Small Intestine Bacterial Overgrowth (SIBO) is implicated in majority of the cases of irritable bowel syndrome (1). Beyond digestive disorders, SIBO has also been shown to have a positive correlation with a wide spectrum of diseases including Alzheimer’s (2), Parkinsons (3), Multiple Sclerosis (4), Coronary Artery Disease (5), Psoriasis (6), and Cancer (7). The treatment of SIBO is multi-faceted, but a major aspect is addressing bacterial overgrowth via use of antibiotics.
Read more